Humana Adds ChemoFx Assay to Medicaid Coverage for Gynecologic Cancers
2 reports, 1 independent
Updated 00:00
Still developing
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Humana incorporated the ChemoFx Assay into its Medicaid Pharmacogenomics Testing coverage policy for gynecologic cancers. The assay is a commercially available chemoresponse test that measures how a patient's live tumor cells react to chemotherapy agents. The test is billed under CPT codes 81535 and 81536.
From finanznachrichten.de
Why it matters
The inclusion of the ChemoFx Assay expands the availability of patient-specific information regarding tumor response to chemotherapy agents. This coverage determination allows oncologists to use the test to guide therapeutic selection in gynecologic cancers.
From finanznachrichten.de
Who's involved
- HumanaAmerican managed health care company that adopted the assay into its coverage policy